Professor Richard Cannon has been selected as the new Associate Dean Research for the Division. Richard has been the Director of the Sir John Walsh Research Institute and the Associate Dean Research for the Faculty of Dentistry for the past 3 years.
Trained as a Microbiologist, Richard has an extensive understanding of the research system in New Zealand, having himself sustained a large research group for over twenty years. He and his group have successfully attracted funding from HRC, MBIE, Marsden fund, NIH and commercial partnerships both nationally and overseas. As Richard has been a member of the Division of Health Sciences Research Committee for a number of years, he is very well placed to continue to lead divisional initiatives.
Paul Glue is Professor of Psychological Medicine in the Dunedin School of Medicine, within Otago Medical School at the University of Otago. He graduated MBChB from the University of Otago. He completed his psychiatry training (MRCPsych) in Oxford UK, and was elected FRCPsych in 2010. In 1987 he moved to the US National Institutes of Health for preclinical neuroscience research and completed an MD in clinical psychopharmacology at the University of Bristol, UK in 1992. Since 2009 he has also been working as a consultant psychiatrist for the Southern District Health Board, in adult general psychiatry.
He was involved with translational clinical pharmacology research in the pharmaceutical industry for 18 years (Schering-Plough, Novartis, Pfizer). He has published over 400 papers and abstracts, has 11 patents and several international research awards / prizes. He was involved with the successful development of a number of drugs including pegylated interferon alfa-2b, interferon-ribavirin combinations for chronic hepatitis C, fingolimod for multiple sclerosis, and combination buprenorphine-naltrexone for opioid maintenance treatment. His current research areas include clinical pharmacology, psychopharmacology and clinical trial design. Current active research interests include use of ketamine for treatment-resistant depression and anxiety disorders.
Paul works with the Pro-Vice-Chancellor (Health Sciences) to promote research commercialisation activities in the Division of Health Sciences. Commercialisation of research is about developing new intellectual property from our research into products and services, thereby contributing to the knowledge-based economy of New Zealand. It is also about building links with industry through knowledge transfer (consulting, commercial research contracts) and technology transfer to enhance the product / services of existing companies. These activities require intimate interaction with the University’s Research and Enterprise Office and Otago Innovation Ltd. Together with senior colleagues in the Divisions of Sciences and Health Sciences, Paul aims to encourage and support staff and research students to be involved in commercialisation of their research.
After completing her PhD on the PrP protein associated with bovine spongiform encephalopathy at Edinburgh University, Michele came to Otago to complete a Marsden-funded postdoctoral fellowship in the Department of Biochemistry. Since then she has held a number of positions in the Division of Health Sciences, culminating in her present role.
Michele advises the Pro-Vice-Chancellor on all aspects of research strategy within the Division. This includes development of strategy, responses to government initiatives, and allocation of Divisional funding for research.